Growth Hormone & Igf Research最新文献

{"title":"Corrigendum to “Insulin-like growth Factors I and II receptors in the breast cancer disparity” among African-American women [Growth Hormone & IGF Research 20 (2010) 245–254]","authors":"S. Kalla Singh, Q.W. Tan, C. Brito, M. De León, D. De León","doi":"10.1016/j.ghir.2022.101512","DOIUrl":"10.1016/j.ghir.2022.101512","url":null,"abstract":"","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101512"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000697/pdfft?md5=1f32f18d0090266f856aa4f3c8a9a9ef&pid=1-s2.0-S1096637422000697-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40656079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study","authors":"Elif Tutku Durmuş ,&nbsp;Ayşegül Atmaca ,&nbsp;Mehmet Kefeli ,&nbsp;Sultan Çalışkan ,&nbsp;Ozgur Mete ,&nbsp;Kerim Aslan ,&nbsp;Murat Fidan ,&nbsp;Ramis Çolak ,&nbsp;Buğra Durmuş","doi":"10.1016/j.ghir.2022.101502","DOIUrl":"10.1016/j.ghir.2022.101502","url":null,"abstract":"<div><h3>Purpose</h3><p><span>To determine whether biochemical responses to long-acting forms of first-generation somatostatin analogue (SSA) therapy </span>in patients<span> with acromegaly could be predicted from baseline and postoperative hormone concentrations, and tumor radiological and histopathological characteristics.</span></p></div><div><h3>Methods</h3><p><span>A total of 68 patients with acromegaly for whom postoperative SSA therapy was started were categorized according to their responses to treatment (SSA-responders vs. non-responders). The patients were compared based on their demographic characteristics, hormone levels, magnetic resonance imaging (MRI), and histopathological findings. Receiver-operating-characteristic (ROC) curves were constructed using the </span>predictive factors<span> that were significant in the univariate analysis to determinate the optimal cut-off values.</span></p></div><div><h3>Results</h3><p>The SSA-responders were significantly older (<em>p</em> = 0.041). Lower GH at diagnosis (<em>p</em> = 0.036), the postoperative 1st-week GH level (<em>p</em> = 0.027), baseline GH, insulin-like growth factor-1 (IGF-1) and IGF-1% upper limit of normal (ULN) (<em>p</em> = 0.001, <em>p</em> = 0.006, <em>p</em> = 0.023, respectively) were associated with biochemical response. T2-hypointensity and lower tumor volume were more common in the SSA-responders (<em>p</em> = 0.018, <em>p</em><span> = 0.03, respectively). Compared to sparsely granulated somatotroph tumors, densely granulated somatotroph tumors and other PitNETs causing GH excess including mammosomatotroph and mixed somatotroph and lactotroph tumors were more likely to respond to SSA therapy (</span><em>p</em> = 0.026, <em>p</em> = 0.03, respectively). The cut-off values generated by ROC curve analysis were GH at diagnosis of ≤8.8 ng/mL, GH at baseline of ≤2.69 ng/mL, IGF-1 at baseline ≤461.5 ng/mL, IGF-1% ULN at baseline ≤180.4%, and tumor volume of ≤1.11 cm³ (all <em>p</em> &lt; 0.05). There were no differences between the groups in terms of tumor invasiveness, proliferative activity (mitotic count per 2 mm² and Ki-67 labeling index) and quantitative analyses of T2-weighted MRI.</p></div><div><h3>Conclusion</h3><p>This study underscores that advanced age, low baseline GH and IGF-1 at diagnosis, low tumor volume, densely granulated tumor subtype, and T2 hypointensity may help predict biochemical response to SSA therapy in cases of acromegaly. These variables should be assessed with utmost attention for all patients prior to SSA treatment. In cases of possible resistance to SSA therapy, therapeutic activity should be monitored more closely and other therapies should be administered immediately in the event of poor response.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101502"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10777034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study","authors":"Yasuko Owada ,&nbsp;Mika Okazaki ,&nbsp;Toshiaki Ikeda ,&nbsp;Ryuji Yamamoto ,&nbsp;Kohtaro Minami ,&nbsp;Kenichi Takahashi ,&nbsp;Tohru Hirato ,&nbsp;Yoko Mita ,&nbsp;Tatsuyoshi Yamamoto ,&nbsp;Kazunori Tanizawa ,&nbsp;Hiroyuki Sonoda ,&nbsp;Yuji Sato","doi":"10.1016/j.ghir.2022.101500","DOIUrl":"10.1016/j.ghir.2022.101500","url":null,"abstract":"<div><h3>Objective</h3><p>Under clinical development for patients with growth hormone deficiency, JR-142 is a long-acting growth hormone with a half-life extended by fusion with modified serum albumin. We conducted a Phase 1 study to investigate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of once-weekly subcutaneous administrations of JR-142. The study consisted of two parts: an open-label single ascending dosing study (Part 1), and a randomized, placebo-controlled, assessor-blinded multiple ascending dosing study (Part 2).</p></div><div><h3>Design</h3><p>A total of 31 healthy Japanese male participants were enrolled. In Part 1, seven of them received a single subcutaneous injection of JR-142 each at dosages of 0.15 mg/kg (<em>n</em> = 1), 0.25 mg/kg (<em>n</em> = 2), 0.5 mg/kg (n = 2), or 1.0 mg/kg (n = 2). In Part 2, one weekly subcutaneous injection of JR-142 at 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg or a placebo were given for four weeks to each of the other 24 participants (six in each group). Plasma JR-142 and serum insulin-like growth factor-1 (IGF-1) concentrations were measured for PK and PD assessments. Safety was evaluated on the basis of adverse events (AEs), laboratory tests, and other measures.</p></div><div><h3>Results</h3><p>JR-142 induced dose-dependent increases in the maximum plasma JR-142 concentration (C_max) and the area under the plasma concentration-time curve from time 0 to τ (AUC_0-τ). A similar dose-response relationship was observed in serum IGF-1 concentrations. All trough IGF-1 levels were well sustained one week after the final administrations of JR-142 at the three dosages, while the peak concentrations of IGF-1 remained mildly elevated. No serious AEs were observed, and laboratory tests, including assessment of anti-drug antibodies, uncovered no significant safety issues.</p></div><div><h3>Conclusions</h3><p>Once-weekly subcutaneous injections of JR-142 produced positive dose-dependent PK and PD profiles over the dosage range. Drug accumulation was observed after the four-week administration period but did not raise safety concerns, indicating that JR-142 is well-tolerated in healthy participants. The PD profiles observed in terms of IGF-1 concentrations were also positive, and we believe the encouraging results of this study warrant substantiation in further clinical trials in patients with GHD.</p></div><div><h3>Ethics</h3><p>This clinical study was conducted at one investigational site in Osaka, Japan, where the clinical study and the non-clinical data of JR-142 were reviewed and approved by its Institutional Review Board on 9th May 2019. The study was conducted in compliance with the approved study protocol, the Declaration of Helsinki, 1964, as revised in 2013, and Good Clinical Practice.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101500"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000570/pdfft?md5=69a4b1bfc6e3e032531b77e2fb0c26fe&pid=1-s2.0-S1096637422000570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10415295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment","authors":"Zvi Laron","doi":"10.1016/j.ghir.2022.101503","DOIUrl":"10.1016/j.ghir.2022.101503","url":null,"abstract":"<div><p><span>A number of reports show that high endogenous, or therapeutic administration of human growth hormone (hGH) cause an increase of serum </span>lipoprotein a, Lp(a). Being thrombogenic Lp(a) is an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Hence, it is hypothesized that the recently reported association between childhood hGH treatment and cardiovascular morbidity is probably due to the GH effect on Lp(a) synthesis. It is therefore suggested to determine serum Lp(a) levels before and during hGH treatment in children and adults.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101503"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40364778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients","authors":"Hakan Düğer ,&nbsp;Hayri Bostan ,&nbsp;Hilal Yıldırım Deryol ,&nbsp;Narin Nasıroğlu İmga ,&nbsp;Bekir Uçan ,&nbsp;Murat Çalapkulu ,&nbsp;Sema Hepşen ,&nbsp;Pınar Akhanlı ,&nbsp;Ümran Gül ,&nbsp;Muhammed Erkam Sencar ,&nbsp;Erman Çakal ,&nbsp;Şeyda Özdemir ,&nbsp;Muhammed Kızılgül","doi":"10.1016/j.ghir.2022.101501","DOIUrl":"10.1016/j.ghir.2022.101501","url":null,"abstract":"<div><h3>Background</h3><p>The nadir growth hormone (nGH) during the oral glucose tolerance test<span><span> (OGTT) is the gold standard method for diagnosing acromegaly. A paradoxical growth hormone (GH) response to oral glucose (OG) in acromegaly can be observed. The role of the paradoxical GH response on how the patients with acromegaly respond to the </span>treatment has been addressed in few studies. The aim of this study was to investigate the association between glucose-dependent growth hormone results and and the responses of acromegalic patients to surgical and/or medical therapy following surgery.</span></p></div><div><h3>Material and methods</h3><p><span>This retrospective cohort study included patients with acromegaly who underwent surgery (</span><em>n</em> = 189) or received primary medical treatment (<em>n</em><span> = 9). The mean age was 50.44 ± 12.81 years (M/F: 84/114). The patients were grouped into paradoxical (GH-P) and non-paradoxical (GH-nP) according to GH response to OG and were compared in terms of clinical and pathological features, pituitary tumor size, invasiveness, biochemical profiles, and how they responded to the treatment.</span></p></div><div><h3>Results</h3><p>The mean age, gender distribution, and basal tumor diameter were all similar in both groups (<em>p</em><span> &gt; 0.05). The GH-P group had a higher remission rate in response to medical therapy followed by surgery (83% vs. 55%; </span><em>p</em> <em>=</em> 0.026). Although a higher surgical remission rate in favor of GH-P was observed, it did not reach statistical significance (63% vs. 48%; <em>p</em> <em>=</em> 0.059). Overall treatment response rates were also higher in the GH-P group compared to the GH-nP group (89% vs. 71%; <em>p</em> <em>=</em> 0.005).</p></div><div><h3>Conclusion</h3><p>A paradoxical GH response to OG load may help to predict the response to medical treatment in patients with acromegaly.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101501"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40378907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between gestational diabetes mellitus and bioavailability of insulin-like growth factors and role of their binding proteins","authors":"Kateřina Anderlová ,&nbsp;Anna Cinkajzlová ,&nbsp;Patrik Šimják ,&nbsp;Jana Kloučková ,&nbsp;Helena Kratochvílová ,&nbsp;Zdeňka Lacinová ,&nbsp;Věra Toušková ,&nbsp;Hana Krejčí ,&nbsp;Miloš Mráz ,&nbsp;Antonín Pařízek ,&nbsp;Martin Haluzík ,&nbsp;Michal Kršek","doi":"10.1016/j.ghir.2022.101511","DOIUrl":"10.1016/j.ghir.2022.101511","url":null,"abstract":"<div><h3>Objective</h3><p>Insulin-like growth factors (IGFs) are involved in regulating growth and metabolism and increase insulin sensitivity, improve glucose metabolism, and are potentially related to gestational diabetes mellitus (GDM) and its complications for mothers and fetuses.</p></div><div><h3>Design</h3><p>This study aimed to assess serum levels and cord blood levels of IGF system components in pregnant women with (39 participants) and without GDM (22 participants). Blood samples were obtained at 28–32 and 36–38 weeks of gestation and 6–12 months after delivery. Cord blood samples were obtained during delivery. Results between both groups as well as between single visits were statistically compared.</p></div><div><h3>Results</h3><p>Both IGF1 and IGF2 maternal serum levels did not differ between the GDM and non-GDM groups. However, levels of IGF-binding proteins (IGFBPs) were different. IGFBP4 levels were decreased during pregnancy and after delivery in women with GDM, while IGFBP7 levels were increased during pregnancy in women with GDM. Cord blood IGFBP3 and IGFBP7 levels were increased (<em>p</em> &lt; 0.001 for IGFBP3, <em>p</em> = 0.003 for IGFBP7), while IGFBP4 levels were decreased (p &lt; 0.001) in the GDM group compared with the non-GDM group.</p></div><div><h3>Conclusions</h3><p>Although IGF levels did not differ, changes in their function level could still persist possibly because of the effects of the binding proteins, especially their promoting or inhibitory effects on IGFs. These results should be considered in interpretation of IGF levels.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101511"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000685/pdfft?md5=c03dde2ea02b742dcc8d21ea230f605b&pid=1-s2.0-S1096637422000685-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33518112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of 18 months of GH replacement on cardiovascular risk factors and quality of life in GH deficient adults; a randomized controlled trial using a fixed very low and a standard dose of GH","authors":"Galina Götherström,&nbsp;Gudmundur Johannsson,&nbsp;Johan Svensson","doi":"10.1016/j.ghir.2022.101510","DOIUrl":"10.1016/j.ghir.2022.101510","url":null,"abstract":"<div><h3>Objective</h3><p>Little is known of the effects of a fixed very low dose of growth hormone (GH) replacement on cardiovascular risk factors, bone mass, muscle strength and quality of life (QoL) in hypopituitary patients.</p></div><div><h3>Design/patients/methods</h3><p><span>This was an open-label randomized study performed at a single center. Consecutive hypopituitary patients with adult onset GH deficiency (GHD) and BMI ≥ 27 kg/m</span>² were randomized to receive a very low fixed dose of GH (LG, <em>n</em> = 9) or a standard dose of GH (SG, n = 9). Body composition, glucose and lipid metabolism, bone mineral content (BMC) and density (BMD), muscle strength, and QoL were measured at baseline and after 6, 12 and 18 months.</p></div><div><h3>Results</h3><p><span>The fixed GH dose in LG was 0.1 mg/day. In SG, the mean baseline GH dose of 0.13 mg/day was gradually increased to 0.31 mg/day at study end. Lean body mass<span> (LBM) as measured using DEXA as well as total body water (TBW) and extracellular water (ECW) were increased only in SG (</span></span><em>P</em> &lt; 0.01, <em>P</em><span> &lt; 0.05, and P &lt; 0.01 vs. LG, respectively). There were no between-groups differences in BMD, BMC, insulin sensitivity<span>, lipids, or muscle strength. Finally, although not significant compared with SG, a sustained improvement in QoL was seen in LG according to the QoL-AGHDA questionnaire.</span></span></p></div><div><h3>Conclusion</h3><p><span>In this pilot study, a fixed very low GH dose improved QoL in GHD adults without any induction of fluid retention. Other effects were comparable to those produced by the standard GH dose. Replacement with a very low GH dose could therefore be a treatment option in hypopituitary patients, especially </span>in patients who do not tolerate higher GH dosage.</p><p><em>Trial registration</em></p><p>This study is registered at <span>ClinicalTrials.gov</span><svg><path></path></svg>, EU-nr 2009–016783-37.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"67 ","pages":"Article 101510"},"PeriodicalIF":1.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10416387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone inhibits adipogenic differentiation and induces browning in bovine subcutaneous adipocytes","authors":"Tingting Li,&nbsp;Hui Bai,&nbsp;Haoyuan Fang,&nbsp;Liang Yang,&nbsp;Peishi Yan","doi":"10.1016/j.ghir.2022.101498","DOIUrl":"10.1016/j.ghir.2022.101498","url":null,"abstract":"<div><h3>Objective</h3><p>It is well established that growth hormone (GH) has the ability to stimulate lipolysis<span>. The effects of GH on adipocyte differentiation and browning have not been clearly described. Therefore, the present study aimed to elucidate the role of GH in the differentiation and browning of bovine subcutaneous adipocytes as well as its underlying molecular mechanisms.</span></p></div><div><h3>Methods</h3><p>We first treated bovine subcutaneous preadipocytes<span><span> with different concentrations (0, 10, 100, and 500 ng/mL) of GH for 8 days and measured lipid accumulation and gene expression. Afterward, we treated preadipocytes and mature adipocytes with 500 ng/mL GH and determined differentiation and browning-related indicators. Finally, we investigated the expression of </span>STAT5B in both preadipocytes and mature adipocytes after GH treatment.</span></p></div><div><h3>Results</h3><p><span><span>We demonstrated that GH inhibited lipid accumulation and decreased the expression levels of adipogenic key genes (SCD1, SREBP1, PPARγ, and CEBPα) during adipocyte differentiation. Moreover, we observed that the inhibitory effect of GH on the early stage of adipocyte differentiation (0–2 days) was stronger than that on the later stage of adipocyte differentiation (2–8 days). We also found that GH promoted the expression levels of browning-related genes such as </span>uncoupling protein 1 (UCP1) in mature adipocytes. Concurrently, GH promoted </span>mitochondrial biogenesis and increased the expression levels of mitochondrial biogenesis-related genes. In addition, GH promoted phosphorylation of signal transducers and activator of transcription 5 b (STAT5B) and contributed to translocation of STAT5B to nucleus. After blocking the expression of STAT5B protein, GH weakened the inhibition of adipogenic key genes and reduced the promotion of browning-related genes in bovine subcutaneous adipocytes.</p></div><div><h3>Conclusions</h3><p>GH can inhibit adipocyte differentiation and promote adipocyte browning by regulating STAT5B in bovine subcutaneous adipocytes.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101498"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40639236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do neurosteroids have impact on depression and cognitive functions in cases with acromegaly?","authors":"Esra Hatipoglu ,&nbsp;Yalcin Hacioglu ,&nbsp;Yeliz Polat ,&nbsp;Hilmi Furkan Arslan ,&nbsp;Sena Oner ,&nbsp;Ozlem Balci Ekmekci ,&nbsp;Mutlu Niyazoglu","doi":"10.1016/j.ghir.2022.101496","DOIUrl":"10.1016/j.ghir.2022.101496","url":null,"abstract":"<div><h3>Objective</h3><p>Neurosteroids<span> (NSs) are a distinct hormone group and, they are known for their contribution into the status of mood and cognitive functions. Whether they are also involved in the mood disturbances and cognition in acromegaly is not known. Herein we aimed to evaluate the relation of mood status and cognitive functions with the NS levels in cases with acromegaly.</span></p></div><div><h3>Design</h3><p><span>A total of 33 cases with acromegaly composed the acromegaly group (AG) and, 30 age and gender-matched cases without acromegaly composed the control group (CG). The levels of Allopregnanolone (AP), </span>pregnenolone<span><span> (PRG), 24S-hydroxycholesterol (24OHC), dehydroepiandrosterone (DHEA), </span>dehydroepiandrosterone sulfate<span><span> (DHEAS), androsterone (ADT), GH and IGF-1 were measured in each group. </span>Beck Depression Inventory (BDI) was used to assess depressive symptoms, whereas an extensive neuropsychological assessment with several neurocognitive tests were carried out for each subject by an experienced psychologist.</span></span></p></div><div><h3>Results</h3><p>Cases with acromegaly had lower 24OHC and DHEA levels (<em>p</em> = 0.002 and <em>p</em><span> = 0.007, respectively) in comparison to CG. Of the cognitive functions time to complete 1 s Series was significantly higher and, the scores on Switching Verbal Fluency Test, Boston Naming Test (BNT)-semantic and BNT-phonological, the highest learning point of Oktem Verbal Memory Processes </span><em>Test (</em>VMPT) were significantly lower in cases with acromegaly in comparison to those in controls (<em>p</em> = 0.004, <em>p</em> = 0.01, <em>p</em> &lt; 0.001, <em>p</em> = 0.02 and <em>p</em> = 0.05, respectively). KAS-perseveration errors were higher in CG (<em>p</em> = 0.03). In AG the levels of AP were negatively correlated with the scores on Months backward Test (MBT), Animal Naming Test, Construction, BNT-spontaneous and positively correlated with BNT-incorrect answers; PRG was positively correlated with VMPT-retention scores, ADT was negatively correlated with MBT and 3 s Series scores, DHEAS was positively correlated with VMPT-the highest learning point whereas it was negatively correlated with MBT scores. Additionally, the scores on BDI were positively correlated with DHEA levels in AG.</p></div><div><h3>Conclusion</h3><p>Cognitive changes may be encountered in acromegaly and, neurosteroids may contribute to the changes in certain cognitive functions.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101496"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40602560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A consensus on optimization of care in patients with growth hormone deficiency and mild traumatic brain injury","authors":"Kevin C.J. Yuen ,&nbsp;Brent Masel ,&nbsp;Michael S. Jaffee ,&nbsp;Gregory O'Shanick ,&nbsp;Tamara L. Wexler ,&nbsp;Kent Reifschneider ,&nbsp;Randall J. Urban ,&nbsp;Sophie Hoang ,&nbsp;Nicky Kelepouris ,&nbsp;Andrew R. Hoffman","doi":"10.1016/j.ghir.2022.101495","DOIUrl":"10.1016/j.ghir.2022.101495","url":null,"abstract":"<div><h3>Objective/design</h3><p>Approximately 2.9 million children and adults in the US experience traumatic brain injuries (TBIs) annually, most of which are considered mild. TBI can induce varying consequences on pituitary function, with growth hormone deficiency (GHD) among the more commonly reported conditions. Panels of pediatric and adult endocrinologists, neurologists, physical medicine and rehabilitation specialists, and neuropsychologists convened in February and October 2020 to discuss ongoing challenges and provide strategies for detection and optimal management of patients with mild TBI and GHD.</p></div><div><h3>Results</h3><p>Difficulties include a low rate of seeking medical attention in the population, suboptimal screening tools, cost and complexity of GHD testing, and a lack of consensus regarding when to test or retest for GHD. Additionally, referrals to endocrinologists from other specialists are uncommon. Recommendations from the panels for managing such patients included multidisciplinary guidelines on the diagnosis and management of post-TBI GHD and additional education on long-term metabolic and probable cognitive benefits of GH replacement therapy.</p></div><div><h3>Conclusion</h3><p>As patients of all ages with mild TBI may develop GHD and/or other pituitary deficiencies, a multidisciplinary approach to provide education to endocrinologists, neurologists, neurosurgeons, traumatologists, and other providers and guidelines for the early identification and management of persistent mild TBI-related GHD are urgently needed.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"66 ","pages":"Article 101495"},"PeriodicalIF":1.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637422000521/pdfft?md5=acccc65b7fe6b7d99a90ff1d5754abe5&pid=1-s2.0-S1096637422000521-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40675614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}